DNA damage signals inhibit neutrophil function

Bednarski, Jeffrey J.

doi:10.1182/blood-2015-11-678672

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, to achieve this, most patients will require long term—often life long—treatment. TKIs offer significant improvements in survival and toxicity compared to other treatments for CML but are nonetheless still associated with diminished health-related quality of life 1, 2 While there remains a paucity of evidence-based data on long term outcomes on which to base clinical treatment decisions, 3 the recent literature does include some new evidence for the effects of long term therapy on patients’ lives. We review this recent literature, including drug-related adverse effects and patient-reported symptoms for each of the main treatment options, long term medication adherence, limitations to fertility and pregnancy, effects on cognitive function, ability to work, financial hardships, children and adolescents, unmet needs, and discontinuation of TKIs.…”

Section: Introductionmentioning

confidence: 99%

Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia

Flynn

Atallah

2016

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Since the development of imatinib and other tyrosine kinase inhibitors (TKIs), the prognosis for patients with chronic myeloid leukemia (CML) has markedly improved, such that most patients diagnosed with CML can now expect to live with their disease rather than die from it. However, most patients will require long term treatment, which has deleterious effects on health-related quality of life. We review recent literature on drug-related adverse effects, long term medication adherence, limitations to fertility and pregnancy, effects on cognitive function, ability to work, financial toxicity, pediatric populations, and treatment discontinuation. While patients with CML are fortunate to have excellent therapies available to control their disease, many are unable to lead normal lives, which challenges the notion that research is no longer needed in CML. Curing CML, i.e., no detectable disease and no need for daily medications, should remain the ultimate goal.

show abstract

Section: Introductionmentioning

confidence: 99%